December 2010 Briefing - DermatologyLast Updated: January 03, 2011.
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for December 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Deer-Associated Parapoxvirus Infection Identified
THURSDAY, Dec. 30 (HealthDay News) -- Parapoxvirus infections were identified in two deer hunters in 2009 and, with deer populations on the rise, the potential for deer-associated parapoxvirus infections may also be increasing, according to a report published in the Dec. 30 issue of the New England Journal of Medicine.
Metabolic Syndrome Prevalence High in Psoriasis Patients
TUESDAY, Dec. 28 (HealthDay News) -- The metabolic syndrome occurs substantially more frequently in people with psoriasis than in the general population, according to research published online Dec. 20 in the Archives of Dermatology.
Few Tie Tanning Bed Avoidance to Lower Skin Cancer Risk
TUESDAY, Dec. 21 (HealthDay News) -- Indoor tanning use is higher among women than men, but few individuals of either gender say that avoidance of tanning beds reduces skin cancer risk, according to a study in the December issue of the Archives of Dermatology.
Framingham Risk Score Is Higher in Psoriasis Patients
TUESDAY, Dec. 21 (HealthDay News) -- Patients with psoriasis have an intermediate risk of developing major cardiovascular events as per the Framingham risk score, according to research published in the Dec. 15 issue of The American Journal of Cardiology.
Rash After Cetuximab Is Indicator of Clinical Benefit
MONDAY, Dec. 20 (HealthDay News) -- An acne-like rash among patients with non-small-cell lung cancer (NSCLC) undergoing treatment with cisplatin and vinorelbine plus cetuximab is associated with improved outcomes, according to research published online Dec. 20 in The Lancet Oncology.
Adalimumab Is Superior Treatment for Psoriasis
TUESDAY, Dec. 14 (HealthDay News) -- Adalimumab (ADA) has a superior benefit-risk profile for treatment of psoriasis compared to methotrexate (MTX), according to a report published in the December issue of the Journal of the American Academy of Dermatology.
Complementary Medicine Use for Skin Disorders Has Risen
MONDAY, Dec. 13 (HealthDay News) -- Complementary and alternative medicine (CAM) use is high among people with skin disorders and has increased in this group, according to a report in the December issue of the Journal of the American Academy of Dermatology.
More Skin Cancers Occur on the Left Side of the Body
FRIDAY, Dec. 10 (HealthDay News) -- There is an increased prevalence of left-sided skin cancers compared with right-sided skin cancers, especially in men and particularly with malignant melanoma in situ, according to research published in the December issue of the Journal of the American Academy of Dermatology.
Daily Sunscreen Use May Reduce Melanoma Risk
TUESDAY, Dec. 7 (HealthDay News) -- The use of daily sunscreen among adults may reduce the risk of melanoma, according to a study published online Dec. 6 in the Journal of Clinical Oncology.
Iron Deficiency Not Likely Culprit in Female Hair Loss
FRIDAY, Dec. 3 (HealthDay News) -- Although past research has suggested a correlation between iron deficiency (ID) and female pattern hair loss (FPHL) or chronic telogen effluvium (CTE), a recent population-based study published in the December issue of the Journal of the American Academy of Dermatology finds no such association.
Burnout Driving Away Many Emergency Physicians
THURSDAY, Dec. 2 (HealthDay News) -- Conflicts between work and family and poor on-the-job teamwork contribute to burnout and drive many physicians, particularly emergency physicians, to want to leave their profession, according to a study published online Dec. 1 in the Emergency Medicine Journal.
|Previous: December 2010 Briefing - Cardiology||Next: December 2010 Briefing - Diabetes & Endocrinology|
Reader comments on this article are listed below. Review our comments policy.